Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Purchases 16,692 Shares

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc purchased 16,692 shares of the business’s stock in a transaction on Thursday, December 26th. The shares were bought at an average cost of $14.38 per share, with a total value of $240,030.96. Following the acquisition, the director now directly owns 14,720,931 shares of the company’s stock, valued at $211,686,987.78. This trade represents a 0.11 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Tuesday, December 24th, Ecor1 Capital, Llc acquired 11,958 shares of Zymeworks stock. The shares were bought at an average price of $14.12 per share, with a total value of $168,846.96.

Zymeworks Price Performance

Shares of Zymeworks stock opened at $14.50 on Monday. Zymeworks Inc. has a twelve month low of $7.97 and a twelve month high of $17.70. The business has a 50-day moving average price of $14.27 and a 200-day moving average price of $12.05. The firm has a market cap of $998.73 million, a price-to-earnings ratio of -9.67 and a beta of 1.12.

Zymeworks (NYSE:ZYME) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. The business had revenue of $16.00 million for the quarter, compared to the consensus estimate of $17.90 million. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%. The company’s revenue was down 3.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.41) EPS. On average, equities analysts expect that Zymeworks Inc. will post -1.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Citigroup lifted their price target on shares of Zymeworks from $16.00 to $18.00 and gave the company a “buy” rating in a report on Monday, November 4th. Leerink Partners raised shares of Zymeworks from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $10.00 to $25.00 in a report on Thursday, November 7th. Wells Fargo & Company raised their price target on Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a report on Thursday, December 19th. JPMorgan Chase & Co. raised Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price objective for the company in a research note on Monday, December 16th. Finally, HC Wainwright reissued a “neutral” rating and set a $12.00 target price on shares of Zymeworks in a research note on Friday, November 22nd. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zymeworks currently has an average rating of “Moderate Buy” and an average price target of $19.17.

Institutional Investors Weigh In On Zymeworks

Several large investors have recently bought and sold shares of ZYME. FMR LLC grew its stake in shares of Zymeworks by 84.2% in the 3rd quarter. FMR LLC now owns 3,336 shares of the company’s stock worth $42,000 after buying an additional 1,525 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new stake in Zymeworks during the third quarter worth approximately $47,000. Quest Partners LLC raised its position in Zymeworks by 8,049.6% during the second quarter. Quest Partners LLC now owns 9,209 shares of the company’s stock valued at $78,000 after purchasing an additional 9,096 shares during the period. nVerses Capital LLC bought a new stake in shares of Zymeworks in the 3rd quarter valued at approximately $79,000. Finally, MQS Management LLC purchased a new position in shares of Zymeworks in the 2nd quarter worth approximately $92,000. Institutional investors own 92.89% of the company’s stock.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.